Literature DB >> 11474564

[Prognosis of acute lymphoblastic leukemia in children. Results of the French protocol FRALLE 93].

G Schaison1, M F Auclerc, A Baruchel, T Leblanc, G Leverger.   

Abstract

1,120 children were included in protocol FRALLE 93 from june 1993 to september 1998. Disease Free Survival for the all protocol is 78% +/- 3 and overall survival 83% +/- 3. Various clinical and laboratory features at the time of diagnosis have been correlated with prognosis. They provide a potential mean to stratify patients into treatment subgroups according their relative risk of treatment failure. The identification of these prognostic factors has been an essential element in the design of current therapeutic trials. Prognostic characteristics of childhood ALL include: age, white blood cell count, tumor burden, cytogénétics (chromosome count and chromosomal translocation), immunophenotype and early response to treatment. Molecular biology has been the revolution of the last two decades permitting the cloning of the genes involved in the leukemic process. Finally the new molecular techniques allow a sensitive diagnostic approach to minimal residual disease (MRD). The better detection of MRD must allow a more rational basis for therapeutic intensification for a subset of poor responder patients. A decrease in therapy of very good responders can also be envisaged.

Entities:  

Mesh:

Year:  2001        PMID: 11474564

Source DB:  PubMed          Journal:  Bull Acad Natl Med        ISSN: 0001-4079            Impact factor:   0.144


  3 in total

1.  Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.

Authors:  Andishe Attarbaschi; Georg Mann; Martin Zimmermann; Valentino Conter; Martin Schrappe; Peter Bader; Elena Barisone; Giuseppe Basso; Andrea Biondi; Gunnar Cario; Gianni Cazzaniga; Antonella Colombini; Christian Flotho; Michaela Kuhlen; Peter Lang; Melchior Lauten; Christin Linderkamp; Franco Locatelli; Luca Lo Nigro; Anja Möricke; Felix Niggli; Renate Panzer-Grümayer; Rosanna Parasole; Christina Peters; Maria Caterina Putti; Carmelo Rizzari; Meinolf Suttorp; Maria Grazia Valsecchi
Journal:  Leukemia       Date:  2019-12-05       Impact factor: 11.528

2.  Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998.

Authors:  Isabel Badell; Arturo Muñoz; Jesús Estella; Rafael Fernández-Delgado; Germán Javier; Amparo Verdeguer; Josep Cubells
Journal:  Clin Transl Oncol       Date:  2008-02       Impact factor: 3.405

3.  Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

Authors:  A Desjonquères; P Chevallier; X Thomas; F Huguet; T Leguay; M Bernard; J-O Bay; E Tavernier; A Charbonnier; F Isnard; M Hunault; P Turlure; M Renaud; J-N Bastié; C Himberlin; S Lepretre; B Lioure; V Lhéritier; V Asnafi; K Beldjord; M Lafage-Pochitaloff; M C Béné; N Ifrah; H Dombret
Journal:  Blood Cancer J       Date:  2016-12-09       Impact factor: 11.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.